Compare LLYVA & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LLYVA | PCVX |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | 54700 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.7B |
| IPO Year | N/A | 2020 |
| Metric | LLYVA | PCVX |
|---|---|---|
| Price | $98.12 | $62.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $88.25 |
| AVG Volume (30 Days) | 98.5K | ★ 1.2M |
| Earning Date | 02-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.86 | $28.09 |
| 52 Week High | $99.82 | $65.00 |
| Indicator | LLYVA | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 65.54 |
| Support Level | $77.49 | $42.30 |
| Resistance Level | $98.57 | $65.00 |
| Average True Range (ATR) | 3.15 | 2.28 |
| MACD | 0.61 | 0.62 |
| Stochastic Oscillator | 89.44 | 95.44 |
Liberty Live Holdings Inc consists of its ownership in Live Nation, its wholly owned subsidiary Quint and other minority investments. Quint is a provider of premium sports and entertainment experiences. Through exclusive rights agreements with sports leagues, event organizers, and governing bodies, Quint designs, develops, and sells official ticket-inclusive hospitality and single to multi-day experiential packages that may include on or off-site experiences, transportation, and hotel accommodations, with involvement of Quint personnel throughout the multi-day experiences. Live Nation is one of the live entertainment companies in the world, and the producer of live music concerts in the world, based on total fans that attend Live Nation events as compared to events of other promoters.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.